| Non-Hodgkin Lymphoma (NHL) |
1 |
0.96 |
| HIV Infection |
0 |
0.7 |
| Hodgkin Lymphoma |
0 |
0.61 |
| Mantle Cell Lymphoma |
0 |
0.61 |
| Remission |
0 |
0.56 |
| CT Scan |
0 |
0.48 |
| Lymphoma |
0 |
0.47 |
| Grant |
0 |
0.37 |
| Pain Management |
0 |
0.35 |
| Otolaryngology |
0 |
0.31 |
| Antiretroviral Therapy for HIV Infection |
0 |
0.29 |
| Scan |
0 |
0.28 |
| Positron Emission Tomography |
0 |
0.26 |
| Chronic Lymphocytic Leukemia |
0 |
0.2 |
| Food and Drug Administration (FDA) |
0 |
0.19 |
| Nucleoside Reverse Transcriptase Inhibitors |
0 |
0.19 |
| Platelet Count |
0 |
0.16 |
| Upper Respiratory Tract Infection |
0 |
0.13 |
| Arm Pain |
0 |
0.11 |
| Brachial |
0 |
0.09 |
| Clinical Research |
0 |
0.09 |
| Hemorrhage |
0 |
0.09 |
| Leukemia |
0 |
0.09 |
| Lymphocytes |
0 |
0.09 |
| Pain |
0 |
0.09 |
| Receptors |
0 |
0.09 |
| Refractory |
0 |
0.09 |
| Respiratory Tract |
0 |
0.09 |
| Tyrosine Kinase |
0 |
0.09 |